Variables | Patients with DAH not receiving PLEX (N = 4) | Patients with DAH receiving PLEX (N = 6) | P value |
---|---|---|---|
Demographic data at DAH | |||
Age (years) | 56.5 (21.0) | 65.5 (34.0) | 0.807 |
Male gender (N, (%)) | 2 (50.0) | 3 (50.0) | 1.000 |
MPA vs. GPA (N, (%)) | 3 (75.0) | 4 (66.7) | 0.778 |
ANCA within 4 weeks before DAH (N, (%)) | |||
MPO-ANCA | 3 (75.0) | 2 (33.3) | 0.197 |
PR3-ANCA | 1 (25.0) | 2 (33.3) | 0.778 |
ANCA negativity | 0 (0) | 2 (33.3) | 0197 |
AAV related indices at DAH | |||
BVAS | 16.0 (17.0) | 15.0 (13.5) | 1.000 |
FFS | 2.0 (0) | 2.5 (2.25) | 1.000 |
Steroid pulse at DHA (N, (%)) | 4 (100) | 6 (100) | N/A |
Administered immunosuppressive drugs (N, (%)) | |||
CYC | 4 (100) | 5 (83.3) | 0.389 |
RTX | 0 (0) | 2 (33.3) | 0.197 |
AZA | 3 (75.0) | 1 (16.7) | 0.065 |
MMF | 0 (0) | 2 (33.3) | 0.197 |
TAC | 0 (0) | 1 (16.7) | 0.389 |
None | 0 (0) | 1 (16.7) | 0.389 |
Follow-up duration (days) | 1145.5 (3421.5) | 130.0 (291.8) | 0.080 |
All-cause mortality (N, (%)) | 1 (25.0) | 3 (50.0) | 0.429 |